Web Exclusives

The addition of carboplatin increases response in patients with triple-negative breast cancer without pathogenic BRCA1 and BRCA2 mutations.
Prolonged use of hormonal contraceptives slightly increases the risk for breast cancer.
Intraventricular HER2 CAR T-cell therapy may be an option for patients with HER2+ breast cancer and brain metastasis.
In the phase 3 OlympiAD trial, treatment with olaparib significantly improved progression-free survival and reduced the risk for disease progression or death compared with standard chemotherapy in women with HER2-negative, BRCA-mutated metastatic breast cancer.
PD-L1 positivity in all cells in patients with breast cancer may be a useful prognostic marker based on a recent meta-analysis.
A new analysis shows that there is an ongoing, steady risk for metastatic or distant recurrence of cancer from years 5 to 20 among women with estrogen receptor–positive breast cancer.
After accounting for the benefit of pertuzumab, investigators found that >6 cycles of docetaxel did not significantly improve progression-free or overall survival in patients with HER2-positive, metastatic breast cancer.
Abemaciclib offers a new option for women with HR-positive, HER2-negative advanced metastatic breast cancer.
Five-year analysis of the phase 3 ALTTO trial showed no decided benefit to dual HER2 blockade over single-agent HER2-targeted therapy for the treatment of HER2-positive early-stage breast cancer. However, an indication for dual HER2 blockade use in HER2-positive, estrogen receptor–negative tumors is a possibility.
A modest reduction in the risk for invasive breast cancer was achieved by adding a second HER2-targeted agent to the treatment regimen for women with early-stage HER2+ breast cancer. The results suggest that the strategy may be appropriate in women at highest risk for recurrence.
Page 4 of 18
Results 31 - 40 of 174